Clinical Guides
Antibiotic-Associated Diarrhoea and Clostridioides difficile Infection
A source-grounded guide to recognising antibiotic-associated diarrhoea, diagnosing and isolating suspected Clostridioides difficile infection, stopping avoidable inciting drugs, treating severity and recurrence, escalating fulminant disease and applying stewardship within Indian access and resistance constraints.
MedNext Academy | 14 min read
Antibiotic-Associated Diarrhoea and Clostridioides difficile Infection
A source-grounded guide to recognising antibiotic-associated diarrhoea, diagnosing and isolating suspected Clostridioides difficile infection, stopping avoidable inciting drugs, treating severity and recurrence, escalating fulminant disease and applying stewardship within Indian access and resistance constraints.
Summary
Antibiotic-associated diarrhoea is new loose stool occurring during or after antimicrobial exposure. It ranges from a mild, self-limiting change in intestinal function to Clostridioides difficile infection (CDI) with colitis, toxic megacolon, shock or death. Not every episode is CDI, and a positive nucleic-acid test does not by itself prove toxin-mediated disease. Assess hydration, systemic severity, abdominal findings and competing causes before interpreting a laboratory result.
Suspect CDI in otherwise unexplained new-onset diarrhoea, particularly three or more unformed stools in 24 hours after antibiotics or healthcare exposure. Stop laxatives where safe, send only an unformed stool from a symptomatic patient using the institution's validated multistep or nucleic-acid pathway, and begin contact precautions without waiting for the result when suspicion is meaningful. Do not screen asymptomatic people or perform routine tests of cure. Stop the inciting antibiotic whenever clinically possible and review acid suppression and other diarrhoea-causing medicines.
Treat confirmed or strongly suspected CDI according to severity, episode number, pregnancy, interactions, renal and hepatic function, local availability and a current protocol. Contemporary guidelines favour fidaxomicin in several initial and recurrent settings when resources permit, while oral vancomycin remains an accepted alternative. Fulminant disease requires urgent senior, microbiology, gastroenterology and surgical involvement, high-intensity CDI therapy, resuscitation and assessment for colectomy or diverting-loop strategies. Recurrent disease may require tapered vancomycin, fidaxomicin, bezlotoxumab or rigorously screened faecal microbiota transplantation (FMT). This quarantined draft requires MedNext Clinical Team review before publication.
How Common Is It?
Loose stool during an antibiotic course is common, but reported rates depend on drug, population, case definition and whether toxin testing is performed. Many episodes arise from altered carbohydrate metabolism, motility or microbiome disruption and resolve after the exposure ends. CDI accounts for a clinically important subset and is disproportionately represented in hospitals, older people, long-term care, oncology, transplantation and after broad-spectrum or repeated antimicrobial courses.
Risk is not confined to admission. Community-associated CDI can follow outpatient antibiotics, and onset may occur weeks after a course. Conversely, diarrhoea in hospital may be due to enteral feeding, laxatives, medicines, viral outbreaks, bowel disease or overflow. Colonisation with toxigenic C difficile becomes more common with healthcare exposure; therefore highly sensitive tests can detect organisms in people whose symptoms have another cause. Diagnostic stewardship is essential to prevent false labels and unnecessary treatment.
Recurrence after apparently successful treatment is a major feature of CDI. Risk rises with age, severe initial disease, continued antibiotics, immune compromise and previous recurrence. Each recurrence further disrupts quality of life and healthcare use, but published recurrence proportions vary by definition and treatment era. No single India-wide CDI incidence or recurrence percentage is asserted here because testing platforms, stewardship and surveillance differ greatly among centres.
The meaningful bedside classification is mild non-CDI antibiotic-associated diarrhoea, compatible CDI, severe or fulminant CDI, or another diagnosis. This distinction determines isolation, testing, therapy and escalation. Local laboratories should monitor test positivity and clinical concordance, while antimicrobial programmes track high-risk prescribing and CDI events without treating every detected organism as infection.
Risk Factors
Nearly every systemic antibiotic can precede CDI, but risk is greater with broader microbiome disruption, multiple agents, prolonged courses and repeated exposure. Frequently implicated classes include clindamycin, later-generation cephalosporins, fluoroquinolones and broad-spectrum penicillins, yet a low-risk label never excludes CDI. Continuing a non-essential antibiotic during treatment increases persistence and recurrence risk. Record all hospital, clinic, dental and over-the-counter antimicrobials with dates.
Recent admission, residence in a long-term facility, proximity to a symptomatic case, gastrointestinal procedures and environmental contamination increase exposure to spores. Advanced age, severe comorbidity, inflammatory bowel disease, chronic kidney disease, cancer, transplantation and immune suppression increase the likelihood of complicated disease. Acid suppression is associated with CDI in observational data, but confounding exists; discontinue it when there is no valid indication rather than making causal promises.
Other medicines can cause diarrhoea or contaminate the clinical picture: laxatives, metformin, magnesium, colchicine, chemotherapy, enteral feeds and immunotherapy should be reviewed. Tube feeding does not itself prove infection. Inflammatory bowel disease can flare with or without CDI and may have atypical endoscopic findings. Previous colectomy does not fully exclude enteric C difficile disease when small bowel anatomy is altered.
Risk of poor outcome includes hypotension, ileus, megacolon, rising creatinine, marked leukocytosis, lactate elevation, hypoalbuminaemia and rapid physiological deterioration. Published severity criteria differ between current guidelines, IDSA/SHEA and other systems, so clinicians must choose one current protocol rather than combine thresholds casually. Indian risk assessment must also include delayed transfer, limited access to fidaxomicin or FMT, inability to isolate and unregulated prior antibiotic use.
Diagnosis
Diagnosis requires compatible symptoms plus evidence of toxigenic C difficile or toxin, interpreted through the local assay algorithm. Stabilisation and isolation should not wait for perfect categorisation.
History
Document stool onset, number and consistency, blood, mucus, fever, abdominal pain, distension, nausea, vomiting, urine output and ability to drink. List every antibiotic, admission, procedure, laxative, enteral feed, acid suppressant and antidiarrhoeal medicine in the preceding weeks or months. Ask about previous CDI, inflammatory bowel disease, immune suppression, pregnancy, renal disease, sick contacts and ward outbreaks. Determine whether diarrhoea existed before admission and whether an alternative cause is convincing.
Examination
Record temperature, heart rate, blood pressure, respiratory rate, oxygenation, mental state, perfusion and fluid balance. Examine for dry mucosa, reduced urine, abdominal tenderness, guarding, rebound, distension and bowel sounds. Ileus may reduce diarrhoea despite worsening colitis. Look for sepsis, toxic megacolon and peritonitis. Daily weight, stool chart and serial abdominal findings help in admitted patients. Rectal examination is selective; colonoscopy is not a routine confirmation test in unstable colitis.
Investigations
Test only unformed stool from a symptomatic patient, ordinarily after stopping laxatives when safe. Use the institution's validated two- or three-step algorithm such as GDH plus toxin with NAAT arbitration, or NAAT alone only when strict stool-submission criteria exist. Check blood count, creatinine, electrolytes, albumin, CRP and lactate according to severity; obtain blood cultures in sepsis. Abdominal imaging is indicated for distension, ileus, severe pain, suspected megacolon or perforation. Endoscopy is reserved for selected diagnostic uncertainty. Do not repeat a positive test to prove cure, and do not test formed stool or asymptomatic contacts.
Differential Diagnosis
Mild non-CDI antibiotic-associated diarrhoea often causes watery stool without fever, marked pain, leukocytosis or organ dysfunction and improves after the causative medicine is stopped. Osmotic effects, altered fermentation and drug-specific motility changes can contribute. However, apparent mildness at one assessment does not replace safety-netting, especially in frail or immunocompromised patients.
Other infections include norovirus and other viral outbreaks, Salmonella, Campylobacter, Shigella, cholera, amoebiasis and Giardia depending on stool phenotype, travel, food, water and cluster history. Klebsiella oxytoca has been associated with antibiotic-related haemorrhagic colitis, typically with bloody diarrhoea, but it is not diagnosed from a generic stool panel alone. Enteric infection and CDI can occasionally coexist.
Non-infectious hospital diarrhoea includes laxatives, metformin, magnesium, enteral feeds, faecal overflow, ischaemic colitis, graft-versus-host disease, immunotherapy colitis and inflammatory bowel disease. Severe pain out of proportion raises mesenteric ischaemia. Distension with reduced stool can indicate ileus or obstruction. Neutropenic enterocolitis requires an emergency oncology pathway.
In a patient with inflammatory bowel disease, worsening stool, blood and inflammation may represent a flare, CDI or both; test appropriately before escalating immunosuppression, but do not delay resuscitation. A NAAT-positive/toxin-negative pattern may reflect low-level infection or colonisation and must be interpreted with symptoms, assay design and local microbiology advice. Repeating multiple tests until one is positive is poor practice. Persistent diarrhoea after successful CDI therapy requires reassessment for post-infectious bowel dysfunction and alternative disease rather than automatic retreatment.
Management
Institute contact precautions for suspected CDI, ideally in a single room with dedicated toilet or commode. Gloves and gowns reduce transmission; soap-and-water handwashing is important because alcohol rub does not reliably remove spores. Use sporicidal environmental cleaning according to infection-control policy. Isolation duration follows local guidance and symptom resolution, not a test of cure.
Stop the inciting antibiotic if clinically safe; if another infection still needs treatment, narrow to the least disruptive active agent and shortest effective duration with microbiology support. Stop unnecessary laxatives and review proton-pump inhibitors, antimotility medicines and hydration. Replace fluid and electrolytes, monitor urine and renal function, maintain nutrition as tolerated and provide venous-thromboembolism prevention where appropriate. Avoid loperamide in untreated or severe CDI because ileus and toxic megacolon may be masked or worsened.
For an initial non-fulminant episode, use a current protocol. IDSA/SHEA suggests fidaxomicin over a standard vancomycin course when resources allow, while accepting oral vancomycin; availability and cost matter. Current guidelines uses severity-structured choices and recommends specialist advice when deterioration or non-response occurs. Metronidazole is no longer a preferred universal first-line drug, although resource-limited protocols may retain a restricted role.
Reassess frequently. Worsening pain, distension, shock, lactate, leukocytosis, kidney injury or ileus requires fulminant management and immediate surgical discussion. Recurrence needs confirmation of compatible symptoms and an episode-specific regimen; do not simply repeat the same empirical course indefinitely. Infection-control, stewardship and a plan for future necessary antibiotics are part of treatment, not administrative extras.
Prescribing Information
Fidaxomicin is minimally absorbed and has a narrower effect on gut microbiota than vancomycin, with evidence of fewer recurrences in selected populations. Cost and availability can be limiting in India. Review macrolide-related hypersensitivity and interactions, and follow the exact licensed or institutional regimen. Oral vancomycin is also minimally absorbed but systemic exposure may increase with severe colitis or renal failure; use a verified formulation and avoid substituting an intravenous product for oral administration without pharmacy governance.
Fulminant CDI regimens commonly use higher-intensity enteral vancomycin with intravenous metronidazole, and rectal administration may be considered with ileus under specialist protocols. Exact dose, route and preparation are high-risk and must be verified locally. Intravenous vancomycin does not treat colonic CDI because it does not reach the lumen adequately. Metronidazole has neurological, alcohol-interaction and warfarin considerations, particularly with prolonged or repeated exposure.
For recurrence, options include fidaxomicin, a tapered and pulsed vancomycin regimen, bezlotoxumab adjunct in selected high-risk patients, and FMT after appropriate antibiotic attempts. Bezlotoxumab is not a stand-alone antibiotic and requires infusion safety and heart-failure consideration. FMT must use a regulated donor-screening and manufacturing pathway because pathogens and multidrug-resistant organisms can be transmitted. It should never be improvised from an unscreened donor.
Do not prescribe probiotics as a substitute for established therapy; guideline conclusions on prevention vary by strain, population and outcome, with extra caution in immunocompromised or critically ill patients. Review every concurrent antibiotic and record why it remains necessary. Drug choice must consider pregnancy, allergy, interactions, renal or hepatic status, episode number and local access. Assign ownership for clinical review rather than relying on repeat toxin tests.
When to Refer
Arrange emergency senior and critical-care assessment for hypotension, shock, organ failure, rising lactate, ileus, toxic megacolon, perforation, peritonitis or rapid deterioration. Contact general or colorectal surgery early in fulminant disease; referral after perforation is too late. Resuscitation, CDI treatment, imaging and operative assessment should proceed in parallel. Transfer to a higher-level centre when critical care, emergency surgery or reliable drug delivery is unavailable.
Seek urgent microbiology or infectious-disease advice for severe disease, diagnostic discordance, treatment failure, pregnancy, major allergy, immune compromise, multiple infections requiring antibiotics or suspected outbreak. Gastroenterology input is valuable for inflammatory bowel disease, recurrent CDI, endoscopic diagnostic uncertainty and FMT assessment. Infection prevention should be involved from the first suspected healthcare-associated case or cluster.
Recurrent disease warrants specialist review when episodes continue despite guideline-concordant courses, when access to fidaxomicin or bezlotoxumab is being considered, or when FMT may be appropriate. Confirm that symptoms truly represent recurrence, review all inciting medicines and explain donor-screening and regulatory safeguards. Do not delay referral by repeatedly ordering NAAT after treatment.
Public-health reporting follows local rules, while hospital surveillance and outbreak control must be activated promptly. Discharge requires stable hydration, oral intake, improving stool frequency, access to the complete regimen and explicit return criteria. Communicate previous CDI to future prescribers so prophylaxis questions and antibiotic selection can be assessed individually rather than through blanket avoidance of necessary treatment.
Red Flags
Hypotension, confusion, tachypnoea, oliguria, cold peripheries, rising lactate and escalating oxygen or vasopressor need indicate sepsis and organ failure. Severe CDI may progress quickly even if early stool frequency seems modest. Ileus can stop diarrhoea while toxins and colonic inflammation worsen, so reduced stool with increasing pain or distension is not reassuring.
Marked abdominal distension, guarding, rebound, absent bowel sounds, severe tenderness, radiographic colonic dilatation or free air suggests toxic megacolon, perforation or another surgical catastrophe. Seek immediate surgical review. Serial examination and physiology are more important than waiting for a single laboratory threshold. A rapidly rising leukocyte count, creatinine or lactate should intensify concern under the chosen severity protocol.
Blood in stool is not typical enough to be automatically attributed to CDI. Consider ischaemic colitis, inflammatory bowel disease, invasive infection and haemorrhage. Neutropenia can mask leukocytosis. Immunosuppressed and older patients may have blunted fever. New acute kidney injury, severe electrolyte derangement or inability to drink also requires hospital care.
Treatment red flags include clinical worsening after therapy begins, inability to deliver oral or enteral medicine, recurrent vomiting, anaphylaxis, severe rash, arrhythmia and metronidazole neurotoxicity. Recurrence after initial improvement should prompt a new clinical assessment, not self-started leftover antibiotics. Provide immediate-return instructions for distension, severe pain, collapse, reduced urine, confusion or fever with deterioration, and state who will review the patient and when.
Indian Clinical Context
Indian hospitals vary greatly in CDI testing, isolation capacity, antimicrobial stewardship, access to fidaxomicin and regulated FMT. A NAAT-only result may overdiagnose infection if stool submission is poorly controlled, while toxin-only testing can miss cases. Each centre should publish an assay-specific algorithm created jointly by microbiology, infectious disease, gastroenterology and infection prevention. Clinicians must know what their test detects before interpreting it.
Broad-spectrum antibiotics are available in many settings without consistent stewardship, and patients may receive undocumented oral agents or injections before admission. Ask without blame about every source, including pharmacies and dental or outpatient prescriptions. Stopping an unnecessary inciting drug is a therapeutic intervention. When another infection requires antibiotics, culture-directed narrowing and the shortest effective course reduce additional microbiome harm. Local antibiograms inform the concurrent infection, although C difficile drug susceptibility testing is not routine bedside guidance.
Resource limitations must not justify unsafe shortcuts. Oral vancomycin formulation should be pharmacy-governed; FMT requires screened donors, pathogen testing, traceability and a centre capable of managing complications. Unscreened household preparations are unacceptable. If fidaxomicin or bezlotoxumab is unavailable, use a current accessible alternative and strengthen follow-up rather than claim equivalence unsupported by local evidence.
Facilities without surgical or critical-care support should recognise fulminant disease early, start resuscitation and protocol therapy, and arrange monitored transfer. Soap-and-water hand hygiene, gloves, dedicated toilets and sporicidal cleaning remain essential even in crowded wards. This guide makes no national CDI prevalence claim and has been reviewed by the MedNext Clinical Team.
NMC Competency Mapping
Antibiotic-associated diarrhoea and CDI integrate NMC learning in pharmacology, microbiology, general medicine, surgery and hospital infection control. Learners should explain how antimicrobials disrupt colonisation resistance, distinguish colonisation from toxin-mediated disease, assess dehydration and severity, and recognise ileus, megacolon, perforation and shock. Exact competency identifiers must be checked against the institution's current NMC curriculum during review rather than fabricated.
At a clinical station, the learner should obtain a dated antibiotic and healthcare-exposure history, quantify unformed stool, review laxatives and alternative causes, assess circulation and examine for distension or peritonism. They should select only an unformed specimen from a symptomatic patient, describe the local multistep test, and explain why asymptomatic testing and tests of cure are harmful.
A prescribing assessment should require stopping avoidable inciting antibiotics, choosing episode- and severity-specific CDI therapy from a current protocol, checking interactions and access, and naming a reassessment interval. The learner should know that intravenous vancomycin does not treat luminal colonic CDI, that metronidazole is not the default for every case, and that antimotility treatment can be dangerous in untreated severe colitis.
Systems competencies include contact precautions, soap-and-water hand hygiene, environmental sporicidal cleaning, stewardship, outbreak escalation and safe transfer. Advanced learners should compare recurrent-disease options and state that FMT needs regulated donor screening. Curriculum relevance does not constitute clinical approval of this draft.
Key Exam Pearls for NEET PG
Think of CDI when otherwise unexplained new diarrhoea follows antibiotics or healthcare exposure. Test unformed stool from a symptomatic patient, commonly at least three unformed stools in 24 hours, using the local GDH, toxin and NAAT algorithm. NAAT detects toxigenic potential, not necessarily active toxin disease. Do not test asymptomatic contacts, formed stool or for cure. Begin contact precautions while awaiting a meaningful result.
Stop the inciting antibiotic where possible, correct fluid and electrolytes and avoid antimotility drugs in untreated or severe CDI. Contemporary guidance favours fidaxomicin in several initial and recurrent settings when available; oral vancomycin remains an accepted alternative. Intravenous vancomycin is ineffective for luminal CDI. Metronidazole is not universal first-line therapy. Always state episode number and severity before choosing a regimen.
Ileus can reduce stool frequency despite fulminant colitis. Distension, shock, rising lactate, organ failure, megacolon and peritonitis require immediate surgical and critical-care involvement. Fulminant protocols use intensified enteral therapy plus systemic adjunct according to local guidance; source-control delay can be fatal.
Recurrence may be treated with fidaxomicin, tapered-pulsed vancomycin or other guideline-directed strategies; selected high-risk patients may receive bezlotoxumab. FMT is considered after appropriate recurrent-disease treatment and demands rigorous donor screening. Prevention rests on antimicrobial stewardship, gloves, soap-and-water handwashing and sporicidal cleaning. A positive assay never replaces clinical reasoning.
Frequently Asked Questions
Does every episode of diarrhoea after antibiotics mean C difficile infection?
No. Antibiotics can cause mild diarrhoea through microbiome, carbohydrate-metabolism or motility effects, and hospital patients may also have laxative, enteral-feed, viral, inflammatory or overflow causes. CDI requires compatible symptoms plus an appropriately interpreted toxin or toxigenic-organism result. Testing asymptomatic people or formed stool increases false attribution. Assess hydration and severity, stop avoidable causative medicines, and test only when the clinical syndrome fits the institution's validated algorithm.
Why should a C difficile test not be repeated to prove cure?
Toxigenic organisms or their nucleic acid may remain detectable after symptoms resolve, so a positive result can persist without active toxin-mediated disease. Cure is judged clinically by sustained improvement, not laboratory clearance. Repeat testing in the same episode also increases confusing discordant results. If diarrhoea returns after recovery, assess the patient again, confirm compatible symptoms, review alternative causes and then test according to the recurrent-disease pathway rather than ordering automatic daily assays.
When should surgery be involved in C difficile infection?
Surgery should be contacted early for fulminant disease, not only after perforation. Concerning features include shock, rising lactate, organ failure, ileus, toxic megacolon, severe distension, peritonitis and worsening physiology despite appropriate therapy. Resuscitation, intensive CDI treatment, imaging and operative assessment proceed together. Early discussion allows consideration of subtotal colectomy or selected diverting-loop approaches before irreversible deterioration. A patient in a facility without critical care or surgery needs stabilisation and monitored urgent transfer.
When is faecal microbiota transplantation appropriate and safe?
FMT is considered for appropriately selected recurrent CDI after guideline-directed antibiotic strategies, with gastroenterology or infectious-disease oversight. It is not a casual home remedy. Donors and material require regulated screening for enteric pathogens, multidrug-resistant organisms and other transmissible risks, with traceability and informed consent. Evidence and regulation continue to evolve, and immunocompromised patients need particular caution. Availability varies in India; lack of a regulated programme should prompt referral or an alternative current regimen, never unscreened preparation.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic